HLB INC.

028300· KOSDAQ· Health Care· Health Care Equipment & Services

₩30,050-5.21%

2026-09-18

Financials

Valuation Metrics

HLB INC.'s Market Cap is ₩4.0T. At end of 2025 it was ₩6.8T. Ranked #124 of 2,421 in KR market (top 5%), #12 of 1,640 on KOSDAQ (top 0.7%), #1 of 96 in Health Care Equipment & Services (top 1%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	4.00T KRW	KR#124/2,421 Sec#1/96
Revenue	97.47B KRW	KR#1,431/2,421 Sec#38/96
Net Income	-227.03B KRW	KR—/2,421 Sec—/96
Total Assets	907.98B KRW	KR#505/2,421 Sec#6/96
Net Assets	422.44B KRW	KR#576/2,421 Sec#8/96
Employees	168	KR#1,227/2,421 Sec#40/96
Value
P/B	9.47x	KR#2,345/2,421 Sec#92/96
P/S	41.07x	KR#2,370/2,421 Sec#94/96
FCF Yield	-2.74%	KR—/2,421 Sec—/96
Profitability
ROE	-53.74%	KR#2,287/2,421 Sec#87/96
ROA	-25.00%	KR#2,281/2,421 Sec#84/96
Op. Margin	-100.66%	KR#2,302/2,421 Sec#84/96
Revenue Growth	28.97%	KR#402/2,421 Sec#21/96
Financial Health
Debt Ratio	114.94%	KR#1,676/2,421 Sec#82/96
FCF	-109.53B KRW	KR#2,139/2,421 Sec#85/96
Cash	26.38B KRW	KR#1,081/2,421 Sec#28/96
Current Ratio	0.26x	KR#2,219/2,421 Sec#94/96
Dividend
Div. Growth	0.00%	KR—/2,421 Sec—/96
Performance
1Y Return	-24.21%	KR#1,382/2,421 Sec#31/96
1M Return	-28.62%	KR#2,350/2,421 Sec#92/96
From 52W High	-56.58%	KR#1,723/2,421 Sec#52/96
1Y MDD	-62.39%	KR#1,611/2,421 Sec#56/96
Trading
Volume	1,081,429 shares	KR#126/2,421 Sec#3/96
Trading Value	32.92B KRW	KR#114/2,421 Sec#2/96
Foreign Own.	17.75%	KR#261/2,421 Sec#6/96
Per Share
EPS	-1,704 KRW	KR—/2,421 Sec—/96
BPS	3,172 KRW	KR#1,823/2,421 Sec#57/96

Company Info

CEO 진양곤, 백윤기 (각자대표)

Employees 168

Founded 1985

HQ 세종특별자치시 연동면, KR

Website hlbbio.co.kr

동사는 1985년 설립돼 1996년 코스닥에 상장한 바이오 의약품 회사로, 2023년 선박사업부를 물적분할해 HLB이엔지를 설립함. 헬스케어사업부는 체외진단 의료기기, 의약외품, 의료소모품을 제조·판매하고, Elevar와 Immunomic Therapeutics는 항암제 및 면역치료제를 개발하고 있음. 동사는 첨단 바이오 연구소 설립, 리보세라닙 치료제 FDA 승인 추진 등 혁신신약 개발로 글로벌 성장하고 있음. HLB는 1985년에 설립되었으며 세종특별자치시 연동면에 본사를 두고 있습니다.